Biogen Idec’s Tecfidera Facing Tough Pricing Talks In Germany
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s IQWiG says a lack of appropriate data from Biogen Idec means any added benefit from its oral MS drug over existing therapies cannot be proven.